Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 63

Results For "clinical"

2937 News Found

Maverick Simulation installs 3D anatomage table at Safdarjung Hospital
Medical Device | October 14, 2025

Maverick Simulation installs 3D anatomage table at Safdarjung Hospital

The anatomage table is one of the most advanced 3D real-tissue–based anatomy visualization systems in the world


Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025
Clinical Trials | October 13, 2025

Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025

mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma


Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3
People | October 13, 2025

Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3

Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026


Roche to present latest cancer care data at ESMO 2025
Clinical Trials | October 13, 2025

Roche to present latest cancer care data at ESMO 2025

Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant


Cadila launches allergy relief tablet Dlorfast-M
News | October 13, 2025

Cadila launches allergy relief tablet Dlorfast-M

Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response


Lupin to present Phase 1 Data on STING agonist at the ESMO Congress 2025
Clinical Trials | October 13, 2025

Lupin to present Phase 1 Data on STING agonist at the ESMO Congress 2025

The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors


Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio
News | October 12, 2025

Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases


Novo Nordisk to acquire Akero Therapeutics for $5.2 billion
News | October 12, 2025

Novo Nordisk to acquire Akero Therapeutics for $5.2 billion

Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases


Merck unveils new HIV treatment and prevention data at EACS 2025
R&D | October 12, 2025

Merck unveils new HIV treatment and prevention data at EACS 2025

Merck will showcase results in innovative solutions in HIV treatment and prevention


FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder
Drug Approval | October 11, 2025

FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder

UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults